Answers are grounded in this paper and cite their sources.
This review explores cancer stratification with molecular subtypes to enhance targeted therapy in oncology, indicating significant clinical implications.
[SUMMARY] Cancer originates via cumulative genetic and epigenetic alterations; it is therefore categorized into molecular subtypes by employing techniques such as microarray analysis and next-generation sequencing, which process conclusive genomic and epigenomic information. Such strategies would aid in classifying patients into different groups that can be subjected to distinct molecular target therapies, and to discover novel cancer driver genes and tumor evolution mechanisms, in addition to identifying underlying drug resistance pathways. Recent development of many molecular targeted therapies has resulted in successful clinical treatment of various cancers. Epigenetic anomalies are potentially reversible; hence, reprogramming the epigenetic profile of cancer cells is a promising strategy for devising innovative therapeutic methods. Herein, we review cancer stratification in the context of molecular subtypes and targeted therapy development.
No takes yet. Share an insight, caveat, or question.
Takeno et al. (2021) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: